{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","name":"Research Synthesis: Sirtuin Effects — full paper","doi":"10.17605/OSF.IO/4EWZV","doi_status":"minted","osf_url":"https://osf.io/4ewzv/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_f55b4a3877684deb/chain","content_hash":"sha256:4e352f59de390681db5065dc627c028651289461fb0a9a103ca521970d8c54b8","provenance_passport":{"publication_id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","submission_id":"f0d337bf-960f-4ca1-b055-b16b2c3558f6","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:4e352f59de390681db5065dc627c028651289461fb0a9a103ca521970d8c54b8","persistent_identifiers":{"doi":"10.17605/OSF.IO/4EWZV","osf_url":"https://osf.io/4ewzv/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_f55b4a3877684deb","dw_chain_url":"https://provenance.researka.org/artifacts/claim_f55b4a3877684deb/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","object_type":"publication","parent_object_id":"f0d337bf-960f-4ca1-b055-b16b2c3558f6","title":"Research Synthesis: Sirtuin Effects — full paper","body_markdown":"# Research Synthesis: Sirtuin Effects — full paper\n\n## Abstract\n\nEvidence-honesty note: 34/39 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. 38/39 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.\n\nThis synthesis tests the thesis that evidence for Sirtuin Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.\n\nThe sirtuin family of NAD+-dependent deacylases has been implicated in cardiometabolic health, inflammation, and longevity, yet whether modulating their expression or activity yields clinically meaningful benefit remains unresolved (Wu 2022; Lee 2019).\n\nTo address this question, we conducted an AI-assisted structured evidence synthesis with an auditable retrieval and appraisal trail, prioritizing direct interventional hard-endpoint evidence over mechanistic or preclinical findings.\n\nPreclinical models support a plausible anti-inflammatory role, as NAD+ supplementation improved endothelial function in a SIRT3-dependent manner (Cao 2022), but fenofibrate's anti-inflammatory effect in obese patients was mediated via the SIRT1/fetuin-A axis (Noureldein 2015; P < 0.001).\n\nThe evidence therefore reveals a pronounced context-dependency: context-specific sirtuin-modulation signals emerge most clearly within pharmacological co-interventions in diabetes or dietary supplementation trials, whereas standalone sirtuin-activator interventions show predominantly null or inconsistent effects.\n\nInterpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-sirtuin_effects-v06-DAILY-2026-06-04T09-46-12Z-R2`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-04.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `sirtuin effects aging`\n- `sirtuin effects older adults`\n- `sirtuin effects randomized controlled trial`\n- `sirtuin aging`\n- `sirtuin older adults`\n- `sirtuin randomized controlled trial`\n\n### Eligibility criteria\n- Sources whose primary content addresses sirtuin effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 196 records in the receipt-candidate union, 76 were classified as source candidates and 39 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 196 |\n| Classified source candidates | 76 |\n| No extractable claims | 49 |\n| None-only claim binding | 9 |\n| Mixed partial-or-none claim-binding candidates | 49 |\n| Partial-only claim-binding candidates | 6 |\n| Strict high-confidence sources | 7 |\n| Admitted final sources | 39 |\n\n### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=20; claims=649 | no extracted directional signal in 19/20 sources | 1 direct; 15 indirect; 2 mechanistic; 2 review | limited corpus depth in this outcome class |\n| Cardiometabolic | n=6; claims=328 | no extracted directional signal in 4/6 sources | 5 indirect; 1 review | limited corpus depth in this outcome class |\n| Dosing and Pharmacokinetics | n=4; claims=105 | no extracted directional signal in 4/4 sources | 2 indirect; 2 review | limited corpus depth in this outcome class |\n| Immune and Inflammation | n=3; claims=109 | no extracted directional signal in 3/3 sources | 2 indirect; 1 mechanistic | limited corpus depth in this outcome class |\n| Deficiency Prevalence | n=2; claims=31 | no extracted directional signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |\n| Immune | n=2; claims=31 | no extracted directional signal in 1/2 sources | 1 mechanistic; 1 review | limited corpus depth in this outcome class |\n| Longevity | n=1; claims=2 | unclear signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Muscle Function | n=1; claims=38 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n\nThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.\n\n### Contextual Adjacent Evidence Outcomes\n\n20 included sources were assigned to this outcome class. Directional coding: null=19, positive=1. Directness coding: direct=1, indirect=15, mechanistic=2, review=2.\n\n### Cardiometabolic Outcomes\n\n6 included sources were assigned to this outcome class. Directional coding: null=4, unclear=2. Directness coding: indirect=5, review=1.\n\n### Dosing Pharmacokinetics Outcomes\n\n4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: indirect=2, review=2.\n\n### Immune Inflammation Outcomes\n\n3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, mechanistic=1.\n\n### Deficiency Prevalence Outcomes\n\n2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.\n\n### Immune Outcomes\n\n2 included sources were assigned to this outcome class. Directional coding: negative=1, null=1. Directness coding: mechanistic=1, review=1.\n\n### Longevity Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: indirect=1.\n\n### Muscle Function Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus is weighted toward short-term biomarker and mechanistic endpoints, with no long-term mortality or hard-cardiovascular-outcome randomized trial included. Without a trial powered for all-cause mortality, major adverse cardiac events, or hospitalization, the headline anti-aging claim for sirtuin modulation remains untestable against hard outcomes. This absence constitutes the most consequential gap: the synthesis can describe expression-level shifts but cannot adjudicate whether those shifts translate into clinically meaningful survival benefits.\n\nSeveral conclusions in the synthesis rest on a single study whose finding cannot be replicated within the corpus. When a conclusion depends on a single unreplicated trial, the confidence interval around its true effect is effectively infinite, and any cross-domain synthesis built on that signal carries an elevated risk of overfitting to one dataset.\n\nThe human studies in this corpus are restricted to narrow demographic slices that limit external validity. Paediatric populations, non-diabetic middle-aged adults, and individuals of non-European ancestry are effectively absent from the corpus. Moreover, the preclinical sources — including Shen 2019 (C57BL/6 mice, n = 6 per group) and Liu 2021 (aged-mouse neuroinflammation model) — use rodent strains that may not recapitulate human sirtuin biology across the lifespan, further narrowing the population to whom mechanistic findings can be generalized.\n\nNo study in the corpus measured patient-centered functional endpoints such as gait speed, grip strength, fall incidence, or activities-of-daily-living disability — outcomes that anchor geriatric anti-aging frameworks (Cruz-Jentoft 2019). The literature is dominated by gene-expression and protein-level surrogates: SIRT1 mRNA, SIRT3 activity, NF-κB phosphorylation, and similar molecular readouts. While mechanistically informative, these surrogates carry the risk flagged by Ioannidis 2005 that biomarker associations do not guarantee hard-outcome validity. Additionally, dose–response relationships for sirtuin-activating compounds remain poorly characterized — the resveratrol dose tested by Garcia-Martinez 2023 (1000 mg/day) was not compared against lower or higher doses in the same population, and the cinnamon dose in Davari 2020 yielded non-significant SIRT1 effects (P = 0.29) without a dose-escalation arm. Until functional and hard clinical endpoints are measured alongside sirtuin-expression changes, the translational significance of the observed molecular signals remains indeterminate.\n\n## Conclusion\n\nFor sirtuin effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\n## What This Synthesis Adds\n\nThis synthesis maps 39 included sources on Sirtuin Effects across 8 outcome classes and 218 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 39 curated reference papers, the evidence base for Sirtuin Effects shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Sirtuin Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nAdditional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the mechanism vs clinical between Werida 2023 and Liu 2021 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.\n\nPrior reviews in the corpus (Noureldein 2015) emphasize convergent signals on Sirtuin Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| cardiometabolic | 0 | 6 | null, unclear | direct interventional hard-endpoint gap |\n| immune | 0 | 2 | negative, null | direct interventional hard-endpoint gap |\n| longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap |\n| muscle function | 0 | 1 | null | direct interventional hard-endpoint gap |\n| deficiency prevalence | 0 | 2 | null | direct interventional hard-endpoint gap |\n| dosing and pharmacokinetics | 0 | 4 | null | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 3 | null | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 1 | 19 | null, positive | conflict-resolution gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 6 indirect sources; direction profile: null, unclear |\n| P2 | immune: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: negative, null |\n| P3 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |\n| P4 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P5 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Sirtuin Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Werida 2023; RCT (clinical); tier=A1; directness=direct; N=—; population=type 2 diabetes patients; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.\n- Noureldein 2015; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=immune; direction=negative; representative statistic=P < 0.001.\n- Nowak-Szwed 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.\n- Garcia-Martinez 2023; Observational; tier=B2; directness=indirect; N=—; population=type 2 diabetes patients; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.05.\n- Wu 2022; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=unclear.\n- Nikooyeh 2021; Observational; tier=B2; directness=indirect; N=—; population=type 2 diabetes patients; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.001.\n- Wasserfurth 2021; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.004.\n- Davari 2020; Observational; tier=B2; directness=indirect; N=—; population=type 2 diabetes patients; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.008.\n- Fu 2022; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null.\n- Hwang 2020; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\nAdditional corpus sources included animal/preclinical evidence; - Severity 4 mechanism vs clinical: Werida 2023 vs Liu 2021; Werida 2023 (contextual other, direct) vs Liu 2021 (immune inflammation, mechanistic)\n- Severity 4 mechanism vs clinical: Werida 2023 vs Cao 2022; Werida 2023 (contextual other, direct) vs Cao 2022 (immune, mechanistic)\n- Severity 3 null vs positive: Garcia-Martinez 2023 vs Werida 2023; Garcia-Martinez 2023 (null) vs Werida 2023 (positive) on contextual other\n- Severity 3 null vs positive: Werida 2023 vs Patyal 2024; Werida 2023 (positive) vs Patyal 2024 (null) on contextual other\n- Severity 3 null vs positive: Werida 2023 vs Sayedyousef 2025; Werida 2023 (positive) vs Sayedyousef 2025 (null) on contextual other\n- Severity 3 null vs positive: Werida 2023 vs Jagodzinska 2025; Werida 2023 (positive) vs Jagodzinska 2025 (null) on contextual other\n- Severity 3 null vs positive: Werida 2023 vs Moin 2026; Werida 2023 (positive) vs Moin 2026 (null) on contextual other\n- Severity 3 null vs positive: Werida 2023 vs Gavia-Garcia 2026; Werida 2023 (positive) vs Gavia-Garcia 2026 (null) on contextual other\n\nAdditional corpus sources included animal/preclinical evidence; additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Hajighasem 2018, Cho 2022, Roggerio 2018, Daneshi-Maskooni 2017, Gonzalez-Fernandez 2019, Martinez-Iglesias 2022, Ding 2021, Rigdon 2024, Bodis 2019, Liu 2019, Lilja 2021, Aghasi 2018, Bo 2018, Zhang 2018, Tsai 2021, Shao 2019, Shi 2020, Nyarady 2020, Wan 2022, Biscetti 2024.\n\n## References\n\n- **Nowak-Szwed 2025.** _Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-03013-y. PMID: 41462250.\n- **Garcia-Martinez 2023.** _Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes._ International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24087422. PMID: 37108584.\n- **Wu 2022.** _The sirtuin family in health and disease._ Signal Transduction and Targeted Therapy, 2022. DOI: 10.1038/s41392-022-01257-8. PMID: 36581622.\n- **Werida 2023.** _Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial._ BMC Endocrine Disorders, 2023. DOI: 10.1186/s12902-023-01511-2. PMID: 38001474.\n- **Nikooyeh 2021.** _The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes._ Nutrition & Diabetes, 2021. DOI: 10.1038/s41387-021-00168-x. PMID: 34389701.\n- **Wasserfurth 2021.** _Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training._ Nutrients, 2021. DOI: 10.3390/nu13113824. PMID: 34836079.\n- **Davari 2020.** _Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: a randomized, double blind, and controlled clinical trial._ Nutrition Journal, 2020. DOI: 10.1186/s12937-019-0518-3. PMID: 31901246.\n- **Fu 2022.** _p53/sirtuin 1/NF-κB Signaling Axis in Chronic Inflammation and Maladaptive Kidney Repair After Cisplatin Nephrotoxicity._ Frontiers in Immunology, 2022. DOI: 10.3389/fimmu.2022.925738. PMID: 35874713.\n- **Shen 2019.** _Myricanol rescues dexamethasone‐induced muscle dysfunction via a sirtuin 1‐dependent mechanism._ Journal of Cachexia, Sarcopenia and Muscle, 2019. DOI: 10.1002/jcsm.12393. PMID: 30793539.\n- **Liu 2021.** _Sirtuin 3 protects against anesthesia/surgery-induced cognitive decline in aged mice by suppressing hippocampal neuroinflammation._ Journal of Neuroinflammation, 2021. DOI: 10.1186/s12974-021-02089-z. PMID: 33541361.\n- **Hwang 2020.** _Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion._ Biomolecules, 2020. DOI: 10.3390/biom10101414. PMID: 33036304.\n- **Sayedyousef 2025.** _Taurine, Sirtuin-1 and TNF-α levels in different aged adults with periodontitis: a pilot study._ BMC Oral Health, 2025. DOI: 10.1186/s12903-025-06690-z. PMID: 40847336.\n- **Gavia-Garcia 2026.** _Sechium edule var. nigrum spinosum (Chayote) Increases the mRNA Expression of Genes Encoding Sirtuins in Older Adults with Type 2 Diabetes Mellitus._ Molecules, 2026. DOI: 10.3390/molecules31071182. PMID: 41976223.\n- **Hajighasem 2018.** _Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver._ PeerJ, 2018. DOI: 10.7717/peerj.5522. PMID: 30221089.\n- **Cho 2022.** _Impact of Exercise Intensity on Systemic Oxidative Stress, Inflammatory Responses, and Sirtuin Levels in Healthy Male Volunteers._ International Journal of Environmental Research and Public Health, 2022. DOI: 10.3390/ijerph191811292. PMID: 36141561.\n- **Roggerio 2018.** _Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration._ Nutrients, 2018. DOI: 10.3390/nu10070937. PMID: 30037068.\n- **Cao 2022.** _Sirtuin 3 Dependent and Independent Effects of NAD + to Suppress Vascular Inflammation and Improve Endothelial Function in Mice._ Antioxidants, 2022. DOI: 10.3390/antiox11040706. PMID: 35453391.\n- **Daneshi-Maskooni 2017.** _The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial._ Trials, 2017. DOI: 10.1186/s13063-017-1979-3. PMID: 28592311.\n- **Gonzalez-Fernandez 2019.** _Granulosa-Lutein Cell Sirtuin Gene Expression Profiles Differ between Normal Donors and Infertile Women._ International Journal of Molecular Sciences, 2019. DOI: 10.3390/ijms21010295. PMID: 31906251.\n- **Moin 2026.** _Deciphering the Role of Sirtuin‐1 Gene Polymorphism in Diabetic Nephropathy: A Systematic Review and Meta‐Analysis._ Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/5528647. PMID: 41624996.\n- **Martinez-Iglesias 2022.** _Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease._ Pharmaceutics, 2022. DOI: 10.3390/pharmaceutics14112447. PMID: 36432638.\n- **Ding 2021.** _Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma._ Molecular Medicine Reports, 2021. DOI: 10.3892/mmr.2021.12400. PMID: 34476507.\n- **Rigdon 2024.** _Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults._ Clinical Pharmacology in Drug Development, 2024. DOI: 10.1002/cpdd.1488. PMID: 39587867.\n- **Bodis 2019.** _Serum and follicular fluid levels of sirtuin 1, sirtuin 6, and resveratrol in women undergoing in vitro fertilization: an observational, clinical study._ The Journal of International Medical Research, 2019. DOI: 10.1177/0300060518811228. PMID: 30556451.\n- **Liu 2019.** _Resveratrol inhibits parathyroid hormone-induced apoptosis in human aortic smooth muscle cells by upregulating sirtuin 1._ Renal Failure, 2019. DOI: 10.1080/0886022X.2019.1605296. PMID: 31106631.\n- **Lilja 2021.** _Five Days Periodic Fasting Elevates Levels of Longevity Related Christensenella and Sirtuin Expression in Humans._ International Journal of Molecular Sciences, 2021. DOI: 10.3390/ijms22052331. PMID: 33652686.\n- **Patyal 2024.** _The Role of Sirtuin-1 Isoforms in Regulating Mitochondrial Function._ Current Issues in Molecular Biology, 2024. DOI: 10.3390/cimb46080522. PMID: 39194739.\n- **Aghasi 2018.** _The effects of green cardamom supplementation on blood glucose, lipids profile, oxidative stress, sirtuin-1 and irisin in type 2 diabetic patients: a study protocol for a randomized placebo-controlled clinical trial._ BMC Complementary and Alternative Medicine, 2018. DOI: 10.1186/s12906-017-2068-6. PMID: 29343256.\n- **Bo 2018.** _Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation._ Acta Diabetologica, 2018. DOI: 10.1007/s00592-017-1097-4. PMID: 29330620.\n- **Zhang 2018.** _Crosstalk between gut microbiota and Sirtuin-3 in colonic inflammation and tumorigenesis._ Experimental & Molecular Medicine, 2018. DOI: 10.1038/s12276-017-0002-0. PMID: 29650970.\n- **Tsai 2021.** _Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency._ Experimental & Molecular Medicine, 2021. DOI: 10.1038/s12276-021-00687-8. PMID: 34702956.\n- **Jagodzinska 2025.** _The impact of histone deacetylase inhibition on neurobehavioural outcomes in preclinical models of traumatic and non-traumatic spinal cord injury: a systematic review._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1690997. PMID: 41280930.\n- **Shao 2019.** _Improved mass spectrometry-based activity assay reveals oxidative and metabolic stress as sirtuin-1 regulators._ Redox Biology, 2019. DOI: 10.1016/j.redox.2019.101150. PMID: 30877853.\n- **Shi 2020.** _Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis._ Theranostics, 2020. DOI: 10.7150/thno.49770. PMID: 33052223.\n- **Nyarady 2020.** _Effects of perinatal factors on sirtuin 3, 8-hydroxy-2′- deoxyguanosine, brain-derived neurotrophic factor and serotonin in cord blood and early breast milk: an observational study._ International Breastfeeding Journal, 2020. DOI: 10.1186/s13006-020-00301-z. PMID: 32552911.\n- **Wan 2022.** _Regulation of Mitophagy by Sirtuin Family Proteins: A Vital Role in Aging and Age-Related Diseases._ Frontiers in Aging Neuroscience, 2022. DOI: 10.3389/fnagi.2022.845330. PMID: 35615591.\n- **Lee 2019.** _Sirtuin signaling in cellular senescence and aging._ BMB Reports, 2019. DOI: 10.5483/BMBRep.2019.52.1.290. PMID: 30526767.\n- **Biscetti 2024.** _Evaluation of sirtuin 1 as a predictor of cardiovascular outcomes in diabetic patients with limb-threatening ischemia._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-78576-z. PMID: 39506067.\n- **Noureldein 2015.** _Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis._ Diabetes Res Clin Pract, 2015. DOI: 10.1016/j.diabres.2015.05.043. PMID: 26105582.\n\n### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"Evidence-honesty note: 34/39 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. 38/39 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Sirtuin Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. The sirtuin family of NAD+-dependent deacylases has been implicated in cardiometabolic health, inflammation, and longevity, yet whether modulating their expression or activity yields clinically meaningful benefit remains unresolved (Wu 2022; Lee 2019). To address this question, we conducted an AI-assisted structured evidence synthesis with an auditable retrieval and appraisal trail, prioritizing direct interventional hard-endpoint evidence over mechanistic or preclinical findings. Preclinical models support a plausible anti-inflammatory role, as NAD+ supplementation improved endothelial function in a SIRT3-dependent manner (Cao 2022), but fenofibrate's anti-inflammatory effect in obese patients was mediated via the SIRT1/fetuin-A axis (Noureldein 2015; P < 0.001).","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":39,"selected_count":39,"review_like_count":6,"primary_like_count":33,"year_start":2015,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":null,"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/4EWZV","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"4ewzv","osf_url":"https://osf.io/4ewzv/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"4ewzv","url":"https://osf.io/4ewzv/","doi":"10.17605/OSF.IO/4EWZV"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_f55b4a3877684deb","dw_chain_url":"https://provenance.researka.org/artifacts/claim_f55b4a3877684deb/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_f55b4a3877684deb/chain","dw_source_artifact_id":"source_cfe6775b7d464803","dw_input_artifact_ids":["source_3e14e9692f064303","source_91d44aefcac94428","source_0639ce86938e4ebc","source_94fb8e8c946f4ac9","source_49f5d2e82c824837","source_34c0a99a4ff94e9a"],"dw_step_id":"step_0de25595e0c54cbc","dw_step_hash":"16b6d593dad3c869164830da80f26b9acf308ddae4b8a1e49c7f81aa4b4dfa23","dw_status":"registered","content_hash":"sha256:4e352f59de390681db5065dc627c028651289461fb0a9a103ca521970d8c54b8","sha256":"sha256:4e352f59de390681db5065dc627c028651289461fb0a9a103ca521970d8c54b8"},"created_at":"2026-06-04T13:50:33.131886+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: 34/39 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. 38/39 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_2","claim":"This synthesis tests the thesis that evidence for Sirtuin Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_3","claim":"To address this question, we conducted an AI-assisted structured evidence synthesis with an auditable retrieval and appraisal trail, prioritizing direct interventional hard-endpoint evidence over mechanistic or preclinical findings.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_4","claim":"Preclinical models support a plausible anti-inflammatory role, as NAD+ supplementation improved endothelial function in a SIRT3-dependent manner (Cao 2022), but fenofibrate's anti-inflammatory effect in obese patients was mediated via the SIRT1/fetuin-A axis (Noureldein 2015; P < 0.001).","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_5","claim":"The evidence therefore reveals a pronounced context-dependency: context-specific sirtuin-modulation signals emerge most clearly within pharmacological co-interventions in diabetes or dietary supplementation trials, whereas standalone sirtuin-activator interventions show predominantly null or inconsistent effects.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_6","claim":"Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_7","claim":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-sirtuin_effects-v06-DAILY-2026-06-04T09-46-12Z-R2`.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_8","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_9","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_10","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_11","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_12","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_13","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_14","claim":"| Contextual Adjacent Evidence | n=20; claims=649 | no extracted directional signal in 19/20 sources | 1 direct; 15 indirect; 2 mechanistic; 2 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_15","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_16","claim":"20 included sources were assigned to this outcome class. Directional coding: null=19, positive=1. Directness coding: direct=1, indirect=15, mechanistic=2, review=2.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_17","claim":"6 included sources were assigned to this outcome class. Directional coding: null=4, unclear=2. Directness coding: indirect=5, review=1.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_18","claim":"4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: indirect=2, review=2.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_19","claim":"3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, mechanistic=1.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_20","claim":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_21","claim":"2 included sources were assigned to this outcome class. Directional coding: negative=1, null=1. Directness coding: mechanistic=1, review=1.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_22","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_23","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_24","claim":"Several conclusions in the synthesis rest on a single study whose finding cannot be replicated within the corpus. When a conclusion depends on a single unreplicated trial, the confidence interval around its true effect is effectively infinite, and any cross-domain synthesis built on that signal carries an elevated risk of overfitting to one dataset.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_25","claim":"No study in the corpus measured patient-centered functional endpoints such as gait speed, grip strength, fall incidence, or activities-of-daily-living disability — outcomes that anchor geriatric anti-aging frameworks (Cruz-Jentoft 2019). The literature is dominated by gene-expression and protein-level surrogates: SIRT1 mRNA, SIRT3 activity, NF-κB phosphorylation, and similar molecular readouts. While mechanistically informative, these surrogates carry the risk flagged by Ioannidis 2005 that biomarker associations do not guarantee hard-outcome validity. Additionally, dose–response relationships for sirtuin-activating compounds remain poorly characterized — the resveratrol dose tested by Garcia-Martinez 2023 (1000 mg/day) was not compared against lower or higher doses in the same population, and the cinnamon dose in Davari 2020 yielded non-significant SIRT1 effects (P = 0.29) without a dose-escalation arm. Until functional and hard clinical endpoints are measured alongside sirtuin-expression changes, the translational significance of the observed molecular signals remains indeterminate.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_26","claim":"For sirtuin effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_27","claim":"This synthesis maps 39 included sources on Sirtuin Effects across 8 outcome classes and 218 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_28","claim":"Across 39 curated reference papers, the evidence base for Sirtuin Effects shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Sirtuin Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_29","claim":"Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the mechanism vs clinical between Werida 2023 and Liu 2021 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]},{"claim_id":"claim_30","claim":"Prior reviews in the corpus (Noureldein 2015) emphasize convergent signals on Sirtuin Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.","candidate_sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","content_hash":"sha256:4e352f59de390681db5065dc627c028651289461fb0a9a103ca521970d8c54b8","nodes":[{"id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","type":"publication","title":"Research Synthesis: Sirtuin Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 34/39 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. 38/39 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_2","type":"claim","text":"This synthesis tests the thesis that evidence for Sirtuin Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation."},{"id":"claim_3","type":"claim","text":"To address this question, we conducted an AI-assisted structured evidence synthesis with an auditable retrieval and appraisal trail, prioritizing direct interventional hard-endpoint evidence over mechanistic or preclinical findings."},{"id":"claim_4","type":"claim","text":"Preclinical models support a plausible anti-inflammatory role, as NAD+ supplementation improved endothelial function in a SIRT3-dependent manner (Cao 2022), but fenofibrate's anti-inflammatory effect in obese patients was mediated via the SIRT1/fetuin-A axis (Noureldein 2015; P < 0.001)."},{"id":"claim_5","type":"claim","text":"The evidence therefore reveals a pronounced context-dependency: context-specific sirtuin-modulation signals emerge most clearly within pharmacological co-interventions in diabetes or dietary supplementation trials, whereas standalone sirtuin-activator interventions show predominantly null or inconsistent effects."},{"id":"claim_6","type":"claim","text":"Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_7","type":"claim","text":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-sirtuin_effects-v06-DAILY-2026-06-04T09-46-12Z-R2`."},{"id":"claim_8","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_9","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_10","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_11","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_12","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_13","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_14","type":"claim","text":"| Contextual Adjacent Evidence | n=20; claims=649 | no extracted directional signal in 19/20 sources | 1 direct; 15 indirect; 2 mechanistic; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_15","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_16","type":"claim","text":"20 included sources were assigned to this outcome class. Directional coding: null=19, positive=1. Directness coding: direct=1, indirect=15, mechanistic=2, review=2."},{"id":"claim_17","type":"claim","text":"6 included sources were assigned to this outcome class. Directional coding: null=4, unclear=2. Directness coding: indirect=5, review=1."},{"id":"claim_18","type":"claim","text":"4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: indirect=2, review=2."},{"id":"claim_19","type":"claim","text":"3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, mechanistic=1."},{"id":"claim_20","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2."},{"id":"claim_21","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: negative=1, null=1. Directness coding: mechanistic=1, review=1."},{"id":"claim_22","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_23","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_24","type":"claim","text":"Several conclusions in the synthesis rest on a single study whose finding cannot be replicated within the corpus. When a conclusion depends on a single unreplicated trial, the confidence interval around its true effect is effectively infinite, and any cross-domain synthesis built on that signal carries an elevated risk of overfitting to one dataset."},{"id":"claim_25","type":"claim","text":"No study in the corpus measured patient-centered functional endpoints such as gait speed, grip strength, fall incidence, or activities-of-daily-living disability — outcomes that anchor geriatric anti-aging frameworks (Cruz-Jentoft 2019). The literature is dominated by gene-expression and protein-level surrogates: SIRT1 mRNA, SIRT3 activity, NF-κB phosphorylation, and similar molecular readouts. While mechanistically informative, these surrogates carry the risk flagged by Ioannidis 2005 that biomarker associations do not guarantee hard-outcome validity. Additionally, dose–response relationships for sirtuin-activating compounds remain poorly characterized — the resveratrol dose tested by Garcia-Martinez 2023 (1000 mg/day) was not compared against lower or higher doses in the same population, and the cinnamon dose in Davari 2020 yielded non-significant SIRT1 effects (P = 0.29) without a dose-escalation arm. Until functional and hard clinical endpoints are measured alongside sirtuin-expression changes, the translational significance of the observed molecular signals remains indeterminate."},{"id":"claim_26","type":"claim","text":"For sirtuin effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_27","type":"claim","text":"This synthesis maps 39 included sources on Sirtuin Effects across 8 outcome classes and 218 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_28","type":"claim","text":"Across 39 curated reference papers, the evidence base for Sirtuin Effects shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Sirtuin Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_29","type":"claim","text":"Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the mechanism vs clinical between Werida 2023 and Liu 2021 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over."},{"id":"claim_30","type":"claim","text":"Prior reviews in the corpus (Noureldein 2015) emphasize convergent signals on Sirtuin Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"source_1","type":"source","study":"Nowak-Szwed 2025","year":2025,"doi":"10.1186/s12933-025-03013-y","url":"https://doi.org/10.1186/s12933-025-03013-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Garcia-Martinez 2023","year":2023,"doi":"10.3390/ijms24087422","url":"https://doi.org/10.3390/ijms24087422","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Wu 2022","year":2022,"doi":"10.1038/s41392-022-01257-8","url":"https://doi.org/10.1038/s41392-022-01257-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Werida 2023","year":2023,"doi":"10.1186/s12902-023-01511-2","url":"https://doi.org/10.1186/s12902-023-01511-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Nikooyeh 2021","year":2021,"doi":"10.1038/s41387-021-00168-x","url":"https://doi.org/10.1038/s41387-021-00168-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Wasserfurth 2021","year":2021,"doi":"10.3390/nu13113824","url":"https://doi.org/10.3390/nu13113824","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Davari 2020","year":2020,"doi":"10.1186/s12937-019-0518-3","url":"https://doi.org/10.1186/s12937-019-0518-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_8","type":"source","study":"Fu 2022","year":2022,"doi":"10.3389/fimmu.2022.925738","url":"https://doi.org/10.3389/fimmu.2022.925738","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Liu 2021","year":2021,"doi":"10.1186/s12974-021-02089-z","url":"https://doi.org/10.1186/s12974-021-02089-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_10","type":"source","study":"Hwang 2020","year":2020,"doi":"10.3390/biom10101414","url":"https://doi.org/10.3390/biom10101414","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Sayedyousef 2025","year":2025,"doi":"10.1186/s12903-025-06690-z","url":"https://doi.org/10.1186/s12903-025-06690-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_12","type":"source","study":"Gavia-Garcia 2026","year":2026,"doi":"10.3390/molecules31071182","url":"https://doi.org/10.3390/molecules31071182","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_13","type":"source","study":"Cho 2022","year":2022,"doi":"10.3390/ijerph191811292","url":"https://doi.org/10.3390/ijerph191811292","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_14","type":"source","study":"Cao 2022","year":2022,"doi":"10.3390/antiox11040706","url":"https://doi.org/10.3390/antiox11040706","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_15","type":"source","study":"Moin 2026","year":2026,"doi":"10.1155/jdr/5528647","url":"https://doi.org/10.1155/jdr/5528647","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_16","type":"source","study":"Martinez-Iglesias 2022","year":2022,"doi":"10.3390/pharmaceutics14112447","url":"https://doi.org/10.3390/pharmaceutics14112447","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_17","type":"source","study":"Ding 2021","year":2021,"doi":"10.3892/mmr.2021.12400","url":"https://doi.org/10.3892/mmr.2021.12400","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_18","type":"source","study":"Rigdon 2024","year":2024,"doi":"10.1002/cpdd.1488","url":"https://doi.org/10.1002/cpdd.1488","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_19","type":"source","study":"Lilja 2021","year":2021,"doi":"10.3390/ijms22052331","url":"https://doi.org/10.3390/ijms22052331","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_20","type":"source","study":"Patyal 2024","year":2024,"doi":"10.3390/cimb46080522","url":"https://doi.org/10.3390/cimb46080522","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_21","type":"source","study":"Tsai 2021","year":2021,"doi":"10.1038/s12276-021-00687-8","url":"https://doi.org/10.1038/s12276-021-00687-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_22","type":"source","study":"Jagodzinska 2025","year":2025,"doi":"10.3389/fimmu.2025.1690997","url":"https://doi.org/10.3389/fimmu.2025.1690997","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_23","type":"source","study":"Shi 2020","year":2020,"doi":"10.7150/thno.49770","url":"https://doi.org/10.7150/thno.49770","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_24","type":"source","study":"Wan 2022","year":2022,"doi":"10.3389/fnagi.2022.845330","url":"https://doi.org/10.3389/fnagi.2022.845330","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_25","type":"source","study":"Nyarady 2020","year":2020,"doi":"10.1186/s13006-020-00301-z","url":"https://doi.org/10.1186/s13006-020-00301-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_26","type":"source","study":"Biscetti 2024","year":2024,"doi":"10.1038/s41598-024-78576-z","url":"https://doi.org/10.1038/s41598-024-78576-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_27","type":"source","study":"Shen 2019","year":2019,"doi":"10.1002/jcsm.12393","url":"https://doi.org/10.1002/jcsm.12393","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_28","type":"source","study":"Hajighasem 2018","year":2018,"doi":"10.7717/peerj.5522","url":"https://doi.org/10.7717/peerj.5522","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_29","type":"source","study":"Roggerio 2018","year":2018,"doi":"10.3390/nu10070937","url":"https://doi.org/10.3390/nu10070937","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_30","type":"source","study":"Daneshi-Maskooni 2017","year":2017,"doi":"10.1186/s13063-017-1979-3","url":"https://doi.org/10.1186/s13063-017-1979-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_31","type":"source","study":"Gonzalez-Fernandez 2019","year":2019,"doi":"10.3390/ijms21010295","url":"https://doi.org/10.3390/ijms21010295","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_32","type":"source","study":"Bodis 2019","year":2019,"doi":"10.1177/0300060518811228","url":"https://doi.org/10.1177/0300060518811228","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_33","type":"source","study":"Liu 2019","year":2019,"doi":"10.1080/0886022X.2019.1605296","url":"https://doi.org/10.1080/0886022X.2019.1605296","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_34","type":"source","study":"Aghasi 2018","year":2018,"doi":"10.1186/s12906-017-2068-6","url":"https://doi.org/10.1186/s12906-017-2068-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_35","type":"source","study":"Bo 2018","year":2018,"doi":"10.1007/s00592-017-1097-4","url":"https://doi.org/10.1007/s00592-017-1097-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_36","type":"source","study":"Zhang 2018","year":2018,"doi":"10.1038/s12276-017-0002-0","url":"https://doi.org/10.1038/s12276-017-0002-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_37","type":"source","study":"Shao 2019","year":2019,"doi":"10.1016/j.redox.2019.101150","url":"https://doi.org/10.1016/j.redox.2019.101150","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_38","type":"source","study":"Lee 2019","year":2019,"doi":"10.5483/BMBRep.2019.52.1.290","url":"https://doi.org/10.5483/BMBRep.2019.52.1.290","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_39","type":"source","study":"Noureldein 2015","year":2015,"doi":"10.1016/j.diabres.2015.05.043","url":"https://doi.org/10.1016/j.diabres.2015.05.043","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_40","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_41","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_42","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_43","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_44","type":"source","study":"Cruz-Jentoft 2019","year":null,"doi":"10.1093/ageing/afy169","url":"https://doi.org/10.1093/ageing/afy169","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_45","type":"source","study":"Ioannidis 2005","year":null,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_1","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_2","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_3","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_4","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_5","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_6","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_7","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_8","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_9","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_10","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_11","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_12","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_13","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_14","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_15","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_16","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_17","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_18","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_19","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_20","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_21","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_22","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_23","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_24","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_25","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_26","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_27","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_28","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_29","type":"contains_claim"},{"from":"8306a2c0-a1a4-4556-9e12-fce4eca92589","to":"claim_30","type":"contains_claim"}],"screening":{"identified":39,"screened":39,"excluded":0,"included":39,"included_or_retained":39,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"39 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","screening":{"identified":39,"screened":39,"excluded":0,"included":39,"included_or_retained":39,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"39 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Preclinical models support a plausible anti-inflammatory role, as NAD+ supplementation improved endothelial function in a SIRT3-dependent manner (Cao 2022), but fenofibrate's anti-inflammatory effect in obese patients was mediated via the SIRT1/fetuin-A axis (Noureldein 2015; P < 0.001).","No study in the corpus measured patient-centered functional endpoints such as gait speed, grip strength, fall incidence, or activities-of-daily-living disability — outcomes that anchor geriatric anti-aging frameworks (Cruz-Jentoft 2019). The literature is dominated by gene-expression and protein-level surrogates: SIRT1 mRNA, SIRT3 activity, NF-κB phosphorylation, and similar molecular readouts. While mechanistically informative, these surrogates carry the risk flagged by Ioannidis 2005 that biomarker associations do not guarantee hard-outcome validity. Additionally, dose–response relationships for sirtuin-activating compounds remain poorly characterized — the resveratrol dose tested by Garcia-Martinez 2023 (1000 mg/day) was not compared against lower or higher doses in the same population, and the cinnamon dose in Davari 2020 yielded non-significant SIRT1 effects (P = 0.29) without a dose-escalation arm. Until functional and hard clinical endpoints are measured alongside sirtuin-expression changes, the translational significance of the observed molecular signals remains indeterminate.","For sirtuin effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 39 curated reference papers, the evidence base for Sirtuin Effects shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Sirtuin Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nNowak-Szwed 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGarcia-Martinez 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWu 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWerida 2023,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNikooyeh 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWasserfurth 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDavari 2020,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nFu 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLiu 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHwang 2020,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSayedyousef 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGavia-Garcia 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nCho 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nCao 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMoin 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nMartinez-Iglesias 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDing 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRigdon 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLilja 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nPatyal 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nTsai 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nJagodzinska 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nShi 2020,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWan 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNyarady 2020,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBiscetti 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nShen 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHajighasem 2018,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nRoggerio 2018,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDaneshi-Maskooni 2017,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nGonzalez-Fernandez 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBodis 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLiu 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAghasi 2018,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nBo 2018,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nZhang 2018,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nShao 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLee 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nNoureldein 2015,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n\"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n\"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nCruz-Jentoft 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nIoannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"8306a2c0-a1a4-4556-9e12-fce4eca92589","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Nowak-Szwed 2025","doi":"10.1186/s12933-025-03013-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Garcia-Martinez 2023","doi":"10.3390/ijms24087422","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wu 2022","doi":"10.1038/s41392-022-01257-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Werida 2023","doi":"10.1186/s12902-023-01511-2","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nikooyeh 2021","doi":"10.1038/s41387-021-00168-x","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wasserfurth 2021","doi":"10.3390/nu13113824","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Davari 2020","doi":"10.1186/s12937-019-0518-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Fu 2022","doi":"10.3389/fimmu.2022.925738","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Liu 2021","doi":"10.1186/s12974-021-02089-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hwang 2020","doi":"10.3390/biom10101414","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sayedyousef 2025","doi":"10.1186/s12903-025-06690-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Gavia-Garcia 2026","doi":"10.3390/molecules31071182","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cho 2022","doi":"10.3390/ijerph191811292","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cao 2022","doi":"10.3390/antiox11040706","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Moin 2026","doi":"10.1155/jdr/5528647","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Martinez-Iglesias 2022","doi":"10.3390/pharmaceutics14112447","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ding 2021","doi":"10.3892/mmr.2021.12400","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Rigdon 2024","doi":"10.1002/cpdd.1488","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Lilja 2021","doi":"10.3390/ijms22052331","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Patyal 2024","doi":"10.3390/cimb46080522","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Tsai 2021","doi":"10.1038/s12276-021-00687-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Jagodzinska 2025","doi":"10.3389/fimmu.2025.1690997","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Shi 2020","doi":"10.7150/thno.49770","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wan 2022","doi":"10.3389/fnagi.2022.845330","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Nyarady 2020","doi":"10.1186/s13006-020-00301-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Biscetti 2024","doi":"10.1038/s41598-024-78576-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Shen 2019","doi":"10.1002/jcsm.12393","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hajighasem 2018","doi":"10.7717/peerj.5522","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Roggerio 2018","doi":"10.3390/nu10070937","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Daneshi-Maskooni 2017","doi":"10.1186/s13063-017-1979-3","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Gonzalez-Fernandez 2019","doi":"10.3390/ijms21010295","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Bodis 2019","doi":"10.1177/0300060518811228","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Liu 2019","doi":"10.1080/0886022X.2019.1605296","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Aghasi 2018","doi":"10.1186/s12906-017-2068-6","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Bo 2018","doi":"10.1007/s00592-017-1097-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Zhang 2018","doi":"10.1038/s12276-017-0002-0","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Shao 2019","doi":"10.1016/j.redox.2019.101150","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Lee 2019","doi":"10.5483/BMBRep.2019.52.1.290","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Noureldein 2015","doi":"10.1016/j.diabres.2015.05.043","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Cruz-Jentoft 2019","doi":"10.1093/ageing/afy169","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Ioannidis 2005","doi":"10.1371/journal.pmed.0020124","risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}}]}